Biopharma News

Aug 13, 2018
By BioPharm International Editors
The new drug, Onpattro (patisiran), by Alnylam Pharmaceuticals, is in a new class of drugs called small interfering ribonucleic acid (siRNA) treatment.
Aug 07, 2018
By BioPharm International Editors
The European Commission (EC) approved Pfizer’s Trazimera (trastuzumab), a biosimilar to Roche’s Herceptin, to treat certain breast and gastric cancers.
Aug 06, 2018
By BioPharm International Editors
Boehringer Ingelheim joins Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, and Imperial Innovations to form a partnership for developing a new gene therapy to treat cystic fibrosis.
Aug 06, 2018
By BioPharm International Editors
The companies will collaborate on the discovery, development, and commercialization of cell therapies for cancer.
Aug 02, 2018
By BioPharm International Editors
The company broke ground on its $200-million, 120,000-sq-ft biomanufacturing plant in West Greenwich, RI.
Aug 02, 2018
By BioPharm International Editors
Stem-cell developer TiGenix has been acquired by Takeda Pharmaceutical for approximately EUR 520 million (US$604 million).
Aug 01, 2018
BioPharm International
Frustrated by slow market adoption, Gottlieb maps out new plan for biosimilar competition.
Aug 01, 2018
By BioPharm International Editors
The companies will work together to develop novel gamma delta T-cell receptor therapies in various cancers.
Aug 01, 2018
By BioPharm International Editors
GlaxoSmithKline and 23andMe, a personal genomics and biotechnology company, will partner to research and develop new drugs using human genetics.
Jul 28, 2018
By BioPharm International Editors
Novartis is set to partner with MorphoSys and Galapagos in a deal worth up to $1.1 billion to develop and commercialize their joint investigational, fully human, IgG1 monoclonal antibody (mAb) directed against the target IL-17C.
native1_300x100
lorem ipsum